Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 5/20 | 0.52 |
| ▸ | LMNA | P02545 | 5/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | FABP4 | P15090 | 7/20 | 0.40 |
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | FABP3 | P05413 | 1/20 | 0.38 |
| ▸ | NR2F2 | P24468 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | GALR3 | O60755 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16201682 | 0.82 | HDAC6 (0.56) | — | |
| SCHEMBL16201679 | 0.80 | POLB (0.45) | HTTLMNARAB9AFABP4FABP3 | |
| SCHEMBL6690128 | 0.65 | FABP4 (0.86) | FABP4FABP3 | |
| SCHEMBL22761785 | 0.65 | SMN1; SMN2 (0.55) | HTTLMNASMN1; SMN2RAB9ARECQL | |
| SCHEMBL16201680 | 0.65 | GALR3 (0.34) | HTTLMNASMN1; SMN2RAB9ARECQL | |
| SCHEMBL16201677 | 0.65 | TYMS (0.36) | HTTLMNASMN1; SMN2RAB9ARECQL | |
| SCHEMBL6691915 | 0.65 | FABP4 (0.66) | FABP4FABP3 | |
| SCHEMBL25514185 | 0.64 | BRD4 (0.54) | HTTLMNASMN1; SMN2RAB9ARECQL | |
| Bromide SCHEMBL22749631 | 0.64 | SMN1; SMN2 (0.57) | HTTLMNASMN1; SMN2RAB9ARECQL | |
| SCHEMBL16201681 | 0.63 | TYMS (0.34) | HTTLMNASMN1; SMN2RAB9ARECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9345905-B2 | Heterocyclic amides compounds which are HDAC6 inhibitors and used as anti-tumoral agents | NANJING ALLGEN PHARMA CO. LTD. (CN) | 2016-05-24 | — | — | US | disclosed |
| US-20140322229-A1 | HETEROCYCLIC AMIDES COMPOUNDS WHICH ARE HDAC6 INHIBITORS AND USED AS ANTI-TUMORAL AGENTS | BETA PHARMA CANADA INC. (CA) | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140322229-A1 | HETEROCYCLIC AMIDES COMPOUNDS WHICH ARE HDAC6 INHIBITORS AND USED AS ANTI-TUMORAL AGENTS | HDAC6, HDAC1, HDAC7 | HTT 112/4885LMNA 3657/4885SMN1; SMN2 814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.